文献速递肿瘤 PET/CT放射性药物与辐射防护

荧光引导手术示踪剂:花菁染料聚甲川链延长如何改变双模态c[RGDyK]示踪剂的药代动力学

Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer.
PubMed 文献 · J Nucl Med · 2018-02-15

本研究以整合素αvβ3为靶点,用111In-DTPA和Cy3、Cy5或Cy7花菁染料构建双模态c[RGDyK]示踪剂,系统比较聚甲川链长度对光物理性质、稳定性和体内靶向能力的影响。结果显示Cy5衍生物表现最优,肿瘤与本底比值达13.2 ± 1.7,高于Cy3的5.7 ± 0.7和Cy7的4.7 ± 0.7。

要点

  • 花菁染料聚甲川链每变化两个碳原子即显著影响RGD示踪剂的稳定性、亮度和组织穿透。
  • DTPA-Cy5-(SO3)甲基-COOH-c[RGDyK]的非特异性摄取最低、肿瘤与本底比值最高(13.2 ± 1.7)。
  • Cy3和Cy7类似物的肿瘤与本底比值分别为5.7 ± 0.7和4.7 ± 0.7,荧光评估呈相似趋势。

核心结论

  • 花菁染料聚甲川链长度的变化深刻影响荧光成像示踪剂的光物理性质、稳定性和体内靶向能力。
  • 直接比较中,中等链长的Cy5所构建的c[RGDyK]示踪剂优于较短链的Cy3和较长链的Cy7类似物。

研究设计与样本

  • 以整合素αvβ3为靶点,将精氨酰甘氨酰天冬氨酸(RGD)载体功能化连接111In-二乙烯三胺五乙酸(DTPA)螯合物和荧光染料,构建双模态示踪剂。
  • 荧光染料分别为Cy3-(SO3)甲基-COOH(发射波长580 nm)、Cy5-(SO3)甲基-COOH(发射波长680 nm)和Cy7-(SO3)甲基-COOH(发射波长780 nm)。
  • 体外分析示踪剂的光物理性质、血清蛋白结合、化学或光学稳定性及组织信号穿透。
  • 用饱和与竞争实验评估受体亲和力。
  • 在荷瘤小鼠中评估体内生物分布(SPECT成像和每克组织注射剂量百分比),并用临床级多光谱荧光腹腔镜获取体内和离体荧光图像。

主要发现

  • 荧光花菁染料聚甲川链两个碳原子步长的变化显著影响杂合RGD示踪剂的化学和光物理特征(如稳定性、亮度和组织穿透)。
  • DTPA-Cy5-(SO3)甲基-COOH-c[RGDyK]在结构上优于其Cy3和Cy7衍生物。
  • 基于放射性的体内药代动力学评估显示,DTPA-Cy5-(SO3)甲基-COOH-c[RGDyK]的非特异性摄取最低、肿瘤与本底比值最高(13.2 ± 1.7)。
  • Cy3和Cy7类似物的肿瘤与本底比值分别为5.7 ± 0.7和4.7 ± 0.7。
  • 基于荧光的肿瘤可见性评估显示相似趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The potential of receptor-mediated fluorescence-based image-guided surgery tracers is generally linked to the near-infrared emission profile and good-manufacturing-production availability of fluorescent dyes. Surprisingly, little is known about the critical interaction between the structural composition of the dyes and the pharmacokinetics of the tracers. In this study, a dual-modality tracer design was used to systematically and quantitatively evaluate the influence of elongation of the polymethine chain in a fluorescent cyanine dye on the imaging potential of a targeted tracer. Methods: As a model system, the integrin marker αvβ3 was targeted using arginylglycylaspartisc acid [RGD]-based vectors functionalized with a 111In-diethylenetriaminepentaacetic acid (DTPA) chelate and a fluorescent dye: (Cy3-(SO3)methyl-COOH [emission wavelength (λem), 580 nm], Cy5-(SO3)methyl-COOH [λem, 680 nm], or Cy7-(SO3)methyl-COOH [λem, 780 nm]). Tracers were analyzed for differences in photophysical properties, serum protein binding, chemical or optical stability, and signal penetration through tissue. Receptor affinities were evaluated using saturation and competition experiments. In vivo biodistribution (SPECT imaging and percentage injected dose per gram of tissue) was assessed in tumor-bearing mice and complemented with in vivo and ex vivo fluorescence images obtained using a clinical-grade multispectral fluorescence laparoscope. Results: Two carbon-atom-step variations in the polymethine chain of the fluorescent cyanine dyes were shown to significantly influence the chemical and photophysical characteristics (e.g., stability, brightness, and tissue penetration) of the hybrid RGD tracers. DTPA-Cy5-(SO3)methyl-COOH-c[RGDyK] structurally outperformed its Cy3 and Cy7 derivatives. Radioactivity-based evaluation of in vivo tracer pharmacokinetics yielded the lowest nonspecific uptake and highest tumor-to-background ratio for DTPA-Cy5-(SO3)methyl-COOH-c[RGDyK] (13.2 ± 1.7), with the Cy3 and Cy7 analogs trailing at respective tumor-to-background ratios of 5.7 ± 0.7 and 4.7 ± 0.7. Fluorescence-based assessment of tumor visibility revealed a similar trend. Conclusion: These findings underline that variations in the polymethine chain lengths of cyanine dyes have a profound influence on the photophysical properties, stability, and in vivo targeting capabilities of fluorescent imaging tracers. In a direct comparison, the intermediate-length dye (Cy5) yielded a superior c[RGDyK] tracer, compared with the shorter (Cy3) and longer (Cy7) analogs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Buckle T, van Willigen DM, Spa SJ, et al. Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer. J Nucl Med. 2018. PMID: 29449447. doi:10.2967/jnumed.117.205575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。